SAN FRANCISCO — A San Mateo County jury has hit Swiss pharmaceutical company Actelion with a $547 million verdict after finding the company interfered with the development of a hypertension drug by a Japanese company.
The jury on Friday also found Actelion and other defendants acted with malice and is set to deliberate Tuesday on punitive damages.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
